{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:27:51Z","timestamp":1770884871314,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ctrv.2016.09.014","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:23:18Z","timestamp":1475713398000},"page":"200-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation"],"prefix":"10.1016","volume":"50","author":[{"given":"John","family":"Coutsouvelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Avery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2016.09.014_b0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.13215","article-title":"How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation","volume":"168","author":"Carreras","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.09.014_b0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br J Haematol"},{"issue":"29","key":"10.1016\/j.ctrv.2016.09.014_b0015","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.3748\/wjg.v13.i29.3918","article-title":"Veno occlusive disease: update on clinical management","volume":"13","author":"Senzolo","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.09.014_b0020","first-page":"3599","article-title":"Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2016.09.014_b0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.014_b0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1705899","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies","volume":"41","author":"Ho","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2016.09.014_b0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ctrv.2016.09.014_b0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.ctrv.2016.09.014_b0045","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1705528","article-title":"Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT)","volume":"38","author":"Ramasamy","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.014_b0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2016.09.014_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2013.05.001","article-title":"Defibrotide: properties and clinical use of an old\/new drug","volume":"59","author":"Pescador","year":"2013","journal-title":"Vascul Pharmacol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.09.014_b0060","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.bbmt.2013.07.001","article-title":"Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide","volume":"19","author":"Carmona","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.ctrv.2016.09.014_b0065","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbmt.2010.11.019","article-title":"Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation","volume":"17","author":"Palomo","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9823","key":"10.1016\/j.ctrv.2016.09.014_b0070","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2016.09.014_b0075","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2141.2009.07871.x","article-title":"Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan","volume":"147","author":"Cappelli","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.09.014_b0080","first-page":"S298","article-title":"Defibrotide as prophylaxis for veno-occlusive disease in children undergoing allogenic and autologous stem cell transplantation","volume":"41","author":"Gray","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.ctrv.2016.09.014_b0085","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/pbc.21425","article-title":"Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children","volume":"50","author":"Qureshi","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2016.09.014_b0090","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2003-10-3612","article-title":"Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure","volume":"103","author":"Versluys","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2016.09.014_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009311.pub2","article-title":"Interventions for prophylaxis of hepaticveno-occlusive disease in people undergoing haematopoietic stem cell transplantation","author":"Cheuk","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ctrv.2016.09.014_b0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1399-0012.2012.01604.x","article-title":"Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review","volume":"26","author":"Zhang","year":"2012","journal-title":"Clin Transplant"},{"issue":"7","key":"10.1016\/j.ctrv.2016.09.014_b0105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ctrv.2016.09.014_b0110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ctrv.2016.09.014_b0115","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pbc.20934","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease in children","volume":"48","author":"Bulley","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.014_b0120","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.bbmt.2014.11.135","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: an update from the international compassionate use program in 710 patients","volume":"21","author":"Corbacioglu","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.014_b0125","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.bbmt.2014.11.137","article-title":"Updated results from the ongoing US treatment IND study using defibrotide for patients with hepatic veno-occlusive disease","volume":"21","author":"Richardson","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2016.09.014_b0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11531840-000000000-00000","article-title":"Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies","volume":"12","author":"Cefalo","year":"2010","journal-title":"Pediatr Drugs"},{"issue":"6","key":"10.1016\/j.ctrv.2016.09.014_b0135","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1399-3046.2010.01311.x","article-title":"Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children","volume":"14","author":"Hassan","year":"2010","journal-title":"Pediatr Transplant"},{"issue":"4","key":"10.1016\/j.ctrv.2016.09.014_b0140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/pbc.21470","article-title":"Defibrotide in sinusoidal obstruction syndrome: mounting evidence in pediatric patients (Commentary on Qureshi et al., page 831)","volume":"50","author":"Del Toro","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2016.09.014_b0145","first-page":"726B","article-title":"Prophylaxis and treatment of heaptic veno-occlusive disease after pediatric stem cell transplantation","volume":"91","author":"Tsakiras","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2016.09.014_b0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1705696","article-title":"Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease","volume":"40","author":"Dignan","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2016.09.014_b0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12659\/AOT.883811","article-title":"Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation","volume":"18","author":"Park","year":"2013","journal-title":"Ann Transplant"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.014_b0160","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2016.09.014_b0165","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2016.09.014_b0170","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial ofdefibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.014_b0175","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.bbmt.2014.11.138","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease: an analysis of clinical benefit as determined by number needed to treat (NNT) to achieve complete response and to improve survival","volume":"21","author":"Richardson","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2016.09.014_b0180","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.transproceed.2007.01.075","article-title":"Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience","volume":"39","author":"Sucak","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ctrv.2016.09.014_b0185","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.014_b0190","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T19:21:18Z","timestamp":1536348078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216300949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":38,"alternative-id":["S0305737216300949"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.014","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}